Sold as Euthroid-0.5, Euthroid-1, Euthroid-2, Euthroid-3, Thyrolar-0.25 and 5 more. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Liotrix (T4;T3) (sold as Euthroid-0.5, Euthroid-1, Euthroid-2 and others), first approved Nov 21, 1969, with 0 new uses approved and 0 published complete response letters.
| Nov 21, 1969 | Thyrolar-0.25, Thyrolar-2NDA 16807 · New formulation or manufacturer | Allergan | 19 | Discontinued |
| — | Euthroid-0.5, Euthroid-1NDA 16680 | Parke Davis | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Allergan
Parke Davis